Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
08:02am, Thursday, 11'th Sep 2025
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products
Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
06:47pm, Tuesday, 09'th Sep 2025
Zai Lab Limited (NASDAQ:ZLAB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Ying Du - Founder, Chairperson & CEO Joshua Smiley - President
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
10:00am, Saturday, 06'th Sep 2025
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB). Such investors
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
08:00pm, Monday, 01'st Sep 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong fo
Zai Lab Announces Participation in Investor Conferences in September 2025
07:30am, Thursday, 28'th Aug 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical D
Zai Lab Establishes Oncology Scientific Advisory Board
11:00am, Wednesday, 13'th Aug 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is
Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript
10:29pm, Thursday, 07'th Aug 2025
Zai Lab Limited (NASDAQ:ZLAB ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christine Chiou - Senior VP & Head of Investor Relations Joshua L. Smiley - President & C
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
10:31am, Thursday, 07'th Aug 2025
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street e
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
06:00am, Thursday, 07'th Aug 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with recent product highlights and corp
This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom
01:03pm, Wednesday, 06'th Aug 2025
Zai Lab stock is in a cup-with-handle base before Q2 results due Thursday.
Tesla Rival Leads 5 China Stocks Near Buy Points Amid Trump Trade Truce Hopes
07:45am, Monday, 28'th Jul 2025
Tesla rival Xiaomi has forged a new tight entry, leading five China stocks near buy points. A Trump trade truce with Beijing reportedly will be extended.
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
11:00am, Wednesday, 23'rd Jul 2025
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
07:30am, Thursday, 10'th Jul 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2025 financial results and provide recent corporate upda
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy
